Skip to main content
SpringerLink
Log in

Benign and Malignant Diseases of the Breast

  • Chapter
Surgery

Abstract

Appreciation of the embryological development, anatomy, and physiology of the breast, is critical for the rational evaluation and treatment of benign, somatic breast complaints. Likewise, it is also a key factor in the appropriate selection and performance of surgical procedures, as well as the comprehensive, systematic application of adjuvant radiochemotherapy and surveillance of patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tanner JM. Wachstun and Reining dis Menschen. Stuttgart, Germany: Georg Theime Verlag, 1962.

    Google Scholar 

  2. Henderson B, Ross R, Ludd H. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985; 56: 1206–1208.

    CAS  PubMed  Google Scholar 

  3. MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. J Natl Cancer Inst 1973; 50: 21–42.

    CAS  PubMed  Google Scholar 

  4. MacMahon B, Trichopoulos D, Brown J. Age at menarche, probability of ovulation and breast cancer risk. Int J Cancer 1982; 29: 12–16.

    Google Scholar 

  5. Trichopoulos D, Yen S, Brown J. The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. Cancer 1984; 53: 187–192.

    CAS  PubMed  Google Scholar 

  6. Thomas D, Lilienfeld A. Geographic, reproductive, and sociobiological factors. In: Stoll BA, ed. Risk Factors in Breast Cancer. Chicago: Heinemann, 1976: 25–53.

    Google Scholar 

  7. MacMahon B, Cole P, Lin T. Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43: 209–221.

    CAS  PubMed  Google Scholar 

  8. Trichopoulos D, Hsieh C, MacMahon B. Age at any birth and breast cancer risk. Int J Cancer 1983; 31: 701–704.

    CAS  PubMed  Google Scholar 

  9. Brinton J, Hoover R, Fraumeni J. Reproductive factors in aetiology of breast cancer. Br J Cancer 1983; 47: 757–762.

    CAS  PubMed  Google Scholar 

  10. Hadjimichael O, Boyle C, Meigs J. Abortion before first live birth and risk of breast cancer. Br J Cancer 1986; 53: 281–284.

    CAS  PubMed  Google Scholar 

  11. Pike M, Henderson B, Casagrande J. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981; 43: 720–776.

    Google Scholar 

  12. Daling JR, Malone KE, Voigt LF, et al. Risk of breast cancer among young women: Relationship to induced abortion. J Natl Cancer Inst 1994; 86: 1584–1592.

    CAS  PubMed  Google Scholar 

  13. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med 1997; 336: 81–85.

    CAS  PubMed  Google Scholar 

  14. Tavani A, LaVecchia C, Francheschi S, et al. Abortion and breast cancer risk. Int J Cancer 1996; 65: 401–405.

    CAS  PubMed  Google Scholar 

  15. Henderson I. What can a woman do about her risk of dying of breast cancer? Curr Probl Cancer 1990; 14: 166–230.

    Google Scholar 

  16. Miller D, Rosenberg L, Kaufman D. Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol 1989; 129: 269–280.

    CAS  PubMed  Google Scholar 

  17. Bernstein L, Pike M, Krallo M, Henderson B. Update of the Los Angeles study of oral contraceptives and breast cancer. In: Mann R, ed. Oral Contraceptives and Breast Cancer. London: Parthenon Publishing Group, 1990: 169.

    Google Scholar 

  18. Meirik O, Lund E, Adami H Oral contraceptive use and breast cancer in young women. Lancet 1986; 2: 650–653.

    CAS  PubMed  Google Scholar 

  19. McPherson K, Vessey M, Neil A. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987; 56: 653–660.

    CAS  PubMed  Google Scholar 

  20. Carroll K. Experimental evidence of dietary factors and hormone dependent cancers. Cancer Res 1975; 35: 3374–3383.

    CAS  PubMed  Google Scholar 

  21. Willett W, Stampfer M, Colditz G. Dietary fat and risk of breast cancer. N Engl J Med 1987; 316: 22–28.

    CAS  PubMed  Google Scholar 

  22. Garfinkel L, Boffetta P, Stellman S. Alcohol and breast cancer: a cohort study. Prey Med 1988; 17: 686–693.

    CAS  Google Scholar 

  23. Longnecker P, Berlin J, Orz M. A metaanalysis of alcohol consumption in relation to breast cancer risk. JAMA 1988; 206: 652–656.

    Google Scholar 

  24. Harvey E, Schairer C, Brinton L. Alcohol consumption and breast cancer. J Natl Cancer Inst 1987; 78: 657–661.

    CAS  PubMed  Google Scholar 

  25. Veer P, Kok F, Hermus R, Sturmans F. Alcohol dose, frequency, and age at first exposure in relation to the risk of breast cancer. Int J Epidemiol 1989; 18: 511–517.

    Google Scholar 

  26. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467.

    Google Scholar 

  27. Ottman R, King M, Pike M, Henderson B. Practical guide for estimating risk for familial breast cancer. Lancet 1983; 2: 556–558.

    CAS  PubMed  Google Scholar 

  28. Anderson D. Genetic study of breast cancer: identification of a high risk group. Cancer 1974; 34: 1090–1097.

    CAS  PubMed  Google Scholar 

  29. Anderson D, Badzioch M. Bilaterality in familial breast cancer patients. Cancer 1985; 56: 2092–2098.

    CAS  PubMed  Google Scholar 

  30. Tokunaga M, Land C, Yamamoto T, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat Res 1987; 112: 243–272.

    CAS  PubMed  Google Scholar 

  31. Miller A, Howe G, Sherman G. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989; 321: 1285–1289.

    CAS  PubMed  Google Scholar 

  32. Shore R, Hildreth N. Breast cancer among women given x-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 1986; 77: 689–696.

    CAS  PubMed  Google Scholar 

  33. Hildreth N, Shore L, Dvoretsky P. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989; 321: 146–151.

    Google Scholar 

  34. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146–151.

    CAS  PubMed  Google Scholar 

  35. Gail M, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–1886.

    CAS  PubMed  Google Scholar 

  36. National Cancer Institute. http://cancertrials.nci.nih.gov/ 1998.

    Google Scholar 

  37. Lynch HT. Introduction to breast cancer genetics. In: Lynch HT, ed. Genetics and Breast Cancer. New York: Van Nostrand Reinhold, 1992: 1–13.

    Google Scholar 

  38. Miki Y, Swensen J, Shattuck-Eiden D, et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66.

    CAS  PubMed  Google Scholar 

  39. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792.

    CAS  PubMed  Google Scholar 

  40. Claus EB, Schildkraut J, Iversen ES Jr, et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 1998; 90: 1824–1829.

    CAS  PubMed  Google Scholar 

  41. Brody LC, Biesecker BB. Breast cancer susceptibility genes: BRCA1 and BRCA2. Rev Mol Med 1998; 77: 208–226.

    CAS  Google Scholar 

  42. Narod SA, Reuteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17812-q23. Lancet 1991; 338: 82–83.

    CAS  PubMed  Google Scholar 

  43. Akashi-Tanaka S, Fukutomi T, Tukami A, et al. Male breast cancer in patients with a familial history of breast cancer. Surg Today 1996; 26: 975–979.

    CAS  PubMed  Google Scholar 

  44. Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7: 103–107.

    CAS  PubMed  Google Scholar 

  45. Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P1 study. J Natl Cancer Inst 1998; 90: 1371–1388.

    CAS  PubMed  Google Scholar 

  46. Fisher B, Costantino JP, Redmond C, et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989; 320: 479–484.

    CAS  PubMed  Google Scholar 

  47. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without Tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986; 4: 459–471.

    CAS  PubMed  Google Scholar 

  48. Mouridsen H, Palshof T, Patterson J, et al. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978; 5: 137–141.

    Google Scholar 

  49. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with Tamoxifen: preliminary findings from the Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–97.

    CAS  PubMed  Google Scholar 

  50. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98101.

    Google Scholar 

  51. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84.

    CAS  PubMed  Google Scholar 

  52. Adair FE. Clinical manifestations of early cancer of the breast-with a discussion on the subject of biopsy. N Engl J Med 1933; 208: 1250–1255.

    Google Scholar 

  53. Foster RS, Costanza MC. Breast self examination practices and breast cancer survival. Cancer 1984; 53: 999.

    PubMed  Google Scholar 

  54. Semiglazar VF, Moiseyenko VM, Bauli JL, et al. The role of breast self-examination in early breast cancer detection (results of the 5 year USSR/WHO randomized study in Leningrad). Eur J Epidemiol 1992; 8: 498.

    Google Scholar 

  55. Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 1997; 89: 355–365.

    CAS  PubMed  Google Scholar 

  56. Boyd NF, Sutherland HF, Fish EB, et al. Prospective evaluation of physical examination of the breast. Am J Surg 1981; 142: 331.

    CAS  PubMed  Google Scholar 

  57. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study 2: breast cancer detection and death rates among women 50 to 59 years. Can Med Assoc J 1992; 147: 1477.

    CAS  Google Scholar 

  58. Ciatto J, Catalion L, Distante V. Nonpalpable breast lesions detected with mammography: review of 512 consecutive cases. Radiology 1987; 165: 99–102.

    CAS  PubMed  Google Scholar 

  59. Sox HC Jr. Preventive health services in adults. N Engl J Med 1993; 330: 1589.

    Google Scholar 

  60. Fletcher S, Black W, Harris R, et al. Special article: report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85: 1644.

    CAS  PubMed  Google Scholar 

  61. National Institutes of Health. Breast cancer screening for women ages 40–49. NIH Consensus Statement 1997, 45: 1–35.

    Google Scholar 

  62. Morrow M. Surgery in the elderly patient, I: breast disease in elderly women. Surg Clin North Am 1994; 74: 145.

    CAS  PubMed  Google Scholar 

  63. Coleman EA, Feuer EJ, NCI Breast Cancer Screening Consortium Members. Breast cancer screening among women from 65 to 74 years of age in 1987–88 and 1991. Ann Intern Med 1992, 417: 961.

    Google Scholar 

  64. Rimer BK, Ross E, Cristinzio S. Older women’s participation in breast screening. J Gerontol 1992; 47: 85.

    PubMed  Google Scholar 

  65. Wilson TE, Helvie MA, August DA. Breast imaging: breast cancer in elderly patients, early detection with mammography. Radiology 1994; 190: 203.

    CAS  PubMed  Google Scholar 

  66. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). Reston, VA: American College of Radiology, 1993.

    Google Scholar 

  67. Schmidt RA. Stereotactic breast biopsy. CA Cancer J Clin 1994; 44: 172–191.

    Google Scholar 

  68. Al-Sobhi S, Helvie MA, Pass HA, Chang AE. Extent of lumpectomy for breast cancer after diagnosis by stereotactic core versus wire localization biopsy. Ann Surg Oncol (in press).

    Google Scholar 

  69. Dronkers DJ. Stereotaxic core biopsy of breast lesions. Radiology 1992; 183: 631–634.

    CAS  PubMed  Google Scholar 

  70. Parker SH, Lovin JD, Jobe WE, et al. Nonpalpable breast lesions: stereotactic automated large-core biopsies. Radiology 1991; 180: 403–407.

    CAS  PubMed  Google Scholar 

  71. Jackman RJ, Nowels KW, Shepard MJ, et al. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994; 193: 91–95.

    CAS  PubMed  Google Scholar 

  72. Liberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. Am J Roentgenol 1995; 164: 1111–1113.

    CAS  Google Scholar 

  73. Jackman RJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of histologically benign, nonpalpable breast lesions: false-negative results and failed follow up. Radiology 1995; 193: 91–95.

    Google Scholar 

  74. Parker S, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 1994; 193: 359–364.

    CAS  PubMed  Google Scholar 

  75. Food and Drug Administration Medical Devices, Diagnostics, and Instrumentation (“The Grey Sheet”). http://www fda gov/cdrh/ost/appendix_h html 1998; accessed June 30, 1998.

    Google Scholar 

  76. Smith BL, Souba WW. Algorithm and explanation: assessment and management of breast complaints. Common Clin Prob 1995: 1–17.

    Google Scholar 

  77. Pashby NL, Mansel RE, Hughes LE, et al. A clinical trial of evening primrose oil in mastalgia. Br J Surg 1981; 68: 801.

    Google Scholar 

  78. Baker H, Snedecor P. Clinical trial of danazol for benign breast disease. Am Surg 1979; 45: 727.

    CAS  PubMed  Google Scholar 

  79. Lauersen N, Wilson K. The effect of danazol in the treatment of chronic mastitis. Obstet Gynecol 1976; 48: 93.

    CAS  PubMed  Google Scholar 

  80. Mansel R, Preece P, Hughes L. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 1978; 65: 724.

    CAS  PubMed  Google Scholar 

  81. Devitt JE. Management of nipple discharge by clinical findings. Am J Surg 1985; 149: 789.

    CAS  PubMed  Google Scholar 

  82. Leis HP Jr, Greene FL, Cammarata A, et al. Nipple discharge: surgical significance. South Med J 1988; 81: 20.

    PubMed  Google Scholar 

  83. Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill-Livingstone, 1987.

    Google Scholar 

  84. Dixon JM, Dobie V, Laub J, et al. Assessment of the acceptability of conservative management of fibroadenoma of the breast. Br J Surg 1996; 83: 264–265.

    Google Scholar 

  85. Cooper JS, Henson DE, et al. In: Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997: 171–178.

    Google Scholar 

  86. Van Lancker M, Goor C, Sacre R, et al. Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol 1995; 18: 267–272.

    PubMed  Google Scholar 

  87. Frykberg ER, Bland KI. Management of in situ and minimally invasive breast carcinoma. World J Surg 1994; 18: 45.

    CAS  PubMed  Google Scholar 

  88. Page DL, Dupont W, Rogers L, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982; 49: 751–758.

    CAS  PubMed  Google Scholar 

  89. Rosen P, Brown D, Kinne D. The clinical significance of pre-invasive breast carcinoma. Cancer 1980; 46: 919–925.

    CAS  PubMed  Google Scholar 

  90. Fisher B, Costantino JP, Redmond C, et al. Lumpectomy corn-pared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581–1586.

    CAS  PubMed  Google Scholar 

  91. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737–769.

    CAS  PubMed  Google Scholar 

  92. Alpers C, Wellings S. The prevalence of carcinoma in situ in normal and cancer-associated breast. Hum Pathol 1985; 16: 796–807.

    CAS  PubMed  Google Scholar 

  93. Bartow S, Pathak D, Black W, Key C, Teaf S. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. Cancer 1987; 60: 2751–2760.

    CAS  PubMed  Google Scholar 

  94. Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky B. Radiation therapy for intraductal carcinoma: is it an equal alternative? Arch Surg 1991; 126: 424–427.

    CAS  PubMed  Google Scholar 

  95. Kinne D, Petrek J, Osborne M, Fracchia A, De Palo A, Rosen PP. Breast carcinoma in situ. Arch Surg 1989; 124: 33–36.

    CAS  PubMed  Google Scholar 

  96. Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for Tla breast carcinoma: is it indicated? Cancer 1994; 73: 664–667.

    CAS  PubMed  Google Scholar 

  97. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441–452.

    CAS  PubMed  Google Scholar 

  98. Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected duct carcinoma in situ: frequency of local recur-rente following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 618.

    CAS  PubMed  Google Scholar 

  99. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818–1822.

    CAS  PubMed  Google Scholar 

  100. Wolmark N, Dignam J, Fisher B. The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): Preliminary results of NSABP protocol B24 [abstract]. Br Cancer Res Treat 1998; 50: 227.

    Google Scholar 

  101. Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast (1960–1969). Cancer 1971; 28: 1182.

    CAS  PubMed  Google Scholar 

  102. Weber BL, Heise H, Neifield JP, et al. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma. Cancer 1981; 47: 2928.

    Google Scholar 

  103. Schwartz G, Feig S, Rosenberg A. Staging and treatment of clinically occult breast cancer. Cancer 1984; 53: 1379.

    CAS  PubMed  Google Scholar 

  104. Wheeler J, Enterline H, Rosenman J. Lobular carcinoma in situ of the breast. Long-term follow-up. Cancer 1974; 34: 554–563.

    CAS  PubMed  Google Scholar 

  105. Frykberg E, Santiago F, Betsill W, O’Brien P. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet 1987; 164: 285–301.

    CAS  PubMed  Google Scholar 

  106. McDivitt R, Hutter R, Foote F, Stewart F. In situ lobular carcinoma. A prospective follow up study indicating cumulative patient risks. JAMA 1967; 201: 82–86.

    CAS  PubMed  Google Scholar 

  107. Rosen P, Lieberman P, Braun D. Lobular carcinoma in situ of the breast. Am J Surg 1978; 2: 225–251.

    CAS  Google Scholar 

  108. Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg 1994; 18: 32.

    CAS  PubMed  Google Scholar 

  109. Rosen PP, Kosloff C, Lieberman P, et al. Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Pathol 1978; 2: 225.

    CAS  Google Scholar 

  110. Fisher ER, Fisher B. Lobular carcinoma of the breast: an overview. Ann Surg 1977; 185: 377.

    CAS  PubMed  Google Scholar 

  111. Broca PP. Traite des tumeurs. Paris: Asselin, 1866.

    Google Scholar 

  112. Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH. Tumor variation in families with breast cancer. JAMA 1972; 222: 1631–1635.

    CAS  PubMed  Google Scholar 

  113. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265–271.

    CAS  PubMed  Google Scholar 

  114. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage [see comments]. Cancer 1996; 77: 697–709.

    CAS  PubMed  Google Scholar 

  115. Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7: 103–107.

    CAS  PubMed  Google Scholar 

  116. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747–752.

    CAS  PubMed  Google Scholar 

  117. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992; 52: 2984–2986.

    CAS  PubMed  Google Scholar 

  118. Brownstein MH, Wolf M, Bikowski JB. Cowden’s disease: a cutaneous marker of breast cancer. Cancer 1978; 41: 2393–2398.

    CAS  PubMed  Google Scholar 

  119. Williard W, Borgen P, Bol R, Tiwari R, Osborne M. Cowden’s disease: a case report with analyses at the molecular level. Cancer 1992; 69: 2969–2974.

    CAS  PubMed  Google Scholar 

  120. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxiatelangiectasia gene to chromosome 11g22–23. Nature 1988; 336: 577–580.

    CAS  PubMed  Google Scholar 

  121. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxiatelangiectasia in the United States. Am J Hum Genet 1986; 39: 573–583.

    CAS  PubMed  Google Scholar 

  122. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185–187.

    CAS  PubMed  Google Scholar 

  123. Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57: 1–7.

    CAS  PubMed  Google Scholar 

  124. Halsted W. The results of operations cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Hosp Bull 1894; 4: 497–555.

    Google Scholar 

  125. Adair FE, Berg J, Joubert L, Robbins GF. Long-term follow-up of breast cancer patients: the 30-year report. Cancer 1974; 33: 1145–1150.

    CAS  PubMed  Google Scholar 

  126. Haagensen CD, Bodian C. A personal experience with Halsted’s radical mastectomy. Ann Surg 1984; 199: 143–150.

    CAS  PubMed  Google Scholar 

  127. Say C, Donegan WL. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 1974; 138: 370–376.

    CAS  PubMed  Google Scholar 

  128. Forrest A, Roberts M, Cant E. Simple mastectomy and pectoral node biopsy: the Cardiff-St. Mary’s Trial. World J Surg 1977; 1: 320–323.

    CAS  PubMed  Google Scholar 

  129. Urban JA. Management of operable breast cancer: the surgeon’s view. Cancer 1978; 42: 2066–2077.

    CAS  PubMed  Google Scholar 

  130. Veronesi U, Valagussa P. Inefficacy of internal mammary node dissection in breast cancer surgery. Cancer 1981; 47: 170–175.

    CAS  PubMed  Google Scholar 

  131. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 10.

    Google Scholar 

  132. Haagensen CD. Diseases of the Breast. 3rd ed. Philadelphia: WB Saunders, 1986.

    Google Scholar 

  133. Robinson G, Van Heerden J, Payne WEA. The primary surgical treatment of carcinoma of the breast: a changing trend toward modified radical mastectomy. Mayo Clin Proc 1976; 51: 433–442.

    CAS  PubMed  Google Scholar 

  134. Baker R, Montague A, Childs J. A comparison of modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer. Ann Surg 1979; 189: 553–559.

    CAS  PubMed  Google Scholar 

  135. Turner L, Swindell R, Bell W. Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl 1981; 63: 239–243.

    CAS  PubMed  Google Scholar 

  136. Maddox W, Carpenter J, Laws H. A randomized prospective trial of radical mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 1983; 198: 207–212.

    CAS  PubMed  Google Scholar 

  137. Maddox W, Carpenter J, Laws H, et al. Does radical mastectomy still have a place in the treatment of primary operable breast cancer? Arch Surg 1987; 122: 1320.

    Google Scholar 

  138. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305: 6.

    CAS  PubMed  Google Scholar 

  139. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized clinical trial. Eur J Cancer 1990; 26: 668.

    CAS  PubMed  Google Scholar 

  140. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822.

    CAS  PubMed  Google Scholar 

  141. Lagios MD, Westdahl PR, Rose M. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981; 16: 83–102.

    CAS  PubMed  Google Scholar 

  142. Holland R, Velig S, Mravunac M, Hendricks J. Histologic multifocality of Tis, T1–2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer 1985; 56: 979–990.

    CAS  PubMed  Google Scholar 

  143. Harris r, Recht A. Conservative surgery and radiotherapy. In: Harris J, Hellman S, Henderson IC, Kinne D, eds. Breast Diseases. Philadelphia: JB Lippincott, 1991: 399–404.

    Google Scholar 

  144. Vicini F, Eberlein T, Connolly J, et al. The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg 1991; 214: 200–205.

    CAS  PubMed  Google Scholar 

  145. Kurtz J, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990; 8: 591–598.

    CAS  PubMed  Google Scholar 

  146. NIH Consensus Development Conference Treatment of early-stage breast cancer. NIH Consens Statement 1990; 8: 1–19.

    Google Scholar 

  147. Fisher B, Montague A, Redmond C, et al. Comparison of radical mastectomy with alternatives for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer 1977; 39: 2827.

    CAS  PubMed  Google Scholar 

  148. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674.

    CAS  PubMed  Google Scholar 

  149. Moffat FL Jr, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: some is good, but all is better. J Surg Oncol 1992; 51: 8–13.

    PubMed  Google Scholar 

  150. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391–395.

    Google Scholar 

  151. Schottenfeld D, Nash AG, Robbins GF, Beattie EJ Jr. Ten-year results of the treatment of primary operable breast carcinoma: a summary of 304 patients evaluated by the TNM system. Cancer 1976; 38: 1001–1007.

    CAS  PubMed  Google Scholar 

  152. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 1170–1178.

    CAS  PubMed  Google Scholar 

  153. Haagensen CD. Treatment of curable carcinoma of the breast. Int J Radiat Oncol Biol Phys 1977; 2: 975–980.

    CAS  PubMed  Google Scholar 

  154. Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528–534.

    CAS  PubMed  Google Scholar 

  155. Payne WS, Taylor WF, Khonsari S, et al. Surgical treatment of breast cancer: trends and factors affecting survival. Arch Surg 1970; 101: 105–113.

    CAS  PubMed  Google Scholar 

  156. Ferguson DJ, Meier P, Karrison T, Dawson PJ, Straus FH, Lowenstein FE. Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA 1982; 248: 1337–1341.

    CAS  PubMed  Google Scholar 

  157. Smith JA III, Gamez-Araujo JJ, Gallager HS, White EC, McBride CM. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39: 527–532.

    PubMed  Google Scholar 

  158. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992; 66: 136–138.

    CAS  PubMed  Google Scholar 

  159. Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer 1996; 74: 2024–2031.

    CAS  PubMed  Google Scholar 

  160. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11: 1536–1544.

    CAS  PubMed  Google Scholar 

  161. Hladiuk M, Huchcroft S, Temple W, et al. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Orcol 1992; 50: 47–52.

    Google Scholar 

  162. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993; 50: 445–449.

    CAS  PubMed  Google Scholar 

  163. Britton RC, Nelson PA. Cause and treatment of postmastectomy lymphedema of the arm: report of 114 cases. JAMA 1962; 180: 95102.

    Google Scholar 

  164. Dewar JA, Sarrazin D, Benhamou E, et al. Management of the axilla in conservatively treated breast cancer: 592 patients treated at Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 1987; 13: 475–481.

    CAS  PubMed  Google Scholar 

  165. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intra-ductal breast cancer. Arch Surg 1990; 125: 1298–1301.

    CAS  PubMed  Google Scholar 

  166. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast: clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982; 6: 401–411.

    CAS  PubMed  Google Scholar 

  167. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391–401.

    CAS  PubMed  Google Scholar 

  168. Turner RR, Ollina DW, Krasne DL, Giuliano AE. Histopatho-logic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 271–276.

    CAS  PubMed  Google Scholar 

  169. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International [Ludwig[Breast Cancer Study Group [see comments]. Lancet 1990; 335: 1565–1568.

    Google Scholar 

  170. Trojani M, de M I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55: 303–306.

    CAS  PubMed  Google Scholar 

  171. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC1 and mRNA and keratin 19 mRNA amplification. Am J Pathol 1996; 148: 649–656.

    CAS  PubMed  Google Scholar 

  172. Danforth DN. The role of axillary lymph node dissection in the management of breast cancer. In: Rosenberg S, Devita V, Hellman S, eds. Principles and Practice of Oncology Updates. Vol. 6. Philadelphia: Lippincott-Raven 1992: 1–16.

    Google Scholar 

  173. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1NOMO/T2NOMO patients with long-term follow-up. J Clin Oncol 1993; 11: 2090–2100.

    CAS  PubMed  Google Scholar 

  174. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473–478.

    CAS  PubMed  Google Scholar 

  175. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [see comments]. J Clin Oncol 1996; 14: 1982–1992.

    CAS  PubMed  Google Scholar 

  176. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–484.

    CAS  PubMed  Google Scholar 

  177. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Natl Cancer Inst 1996; 88: 1529–1542.

    CAS  PubMed  Google Scholar 

  178. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women [see comments]. Lancet 1992; 339: 71–85.

    Google Scholar 

  179. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10: 387–395.

    CAS  PubMed  Google Scholar 

  180. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer [see comments]. N Engl J Med 1996; 334: 1356–1361.

    CAS  PubMed  Google Scholar 

  181. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483–1496.

    CAS  PubMed  Google Scholar 

  182. Bedwinek JM, Lee J, Fineberg B, Ocwieza M. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 1981; 47: 2232–2235.

    CAS  PubMed  Google Scholar 

  183. Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985; 3: 660–665.

    CAS  PubMed  Google Scholar 

  184. Jones JM, Ribeiro GG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy [see comments]. Clin Radiol 1989; 40: 204–208.

    CAS  PubMed  Google Scholar 

  185. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial [see comments]. N Engl J Med 1997; 337: 949–955.

    CAS  PubMed  Google Scholar 

  186. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [see comments]. N Engl J Med 1997; 337: 956–962.

    CAS  PubMed  Google Scholar 

  187. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987; 47: 3889–3894.

    CAS  PubMed  Google Scholar 

  188. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19: 278–285.

    CAS  PubMed  Google Scholar 

  189. Hortobagyi GN, Ames FC, Buzdar AU, et al. Managements of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507–2516.

    CAS  PubMed  Google Scholar 

  190. Hobar PC, Jones RC, Schouten J, Leitch AM, Hendler F. Multi-modality treatment of locally advanced breast carcinoma. Arch Surg 1988; 123: 951–955.

    CAS  PubMed  Google Scholar 

  191. Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988; 6: 261–269.

    CAS  PubMed  Google Scholar 

  192. Lippman ME, Sorace RA, Bagley CS, Danforth DW Jr, Lichter A, Wesley MN. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. Monogr Natl Cancer Inst 1986: 1: 153–159.

    Google Scholar 

  193. Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765–1771.

    CAS  PubMed  Google Scholar 

  194. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast, II: Inflammatory carcinoma. Cancer 1994; 74 (suppl 1]: 466–476.

    CAS  PubMed  Google Scholar 

  195. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: protocol 19 Aredia Breast Cancer Study Group [see comments] N Engl J Med 1996; 335: 1785–1791.

    CAS  Google Scholar 

  196. Paget J. Disease of the mammary areola preceding cancer of the mammary gland. St Bart Hosp Rep 1874; 10: 79–89.

    Google Scholar 

  197. Pierce LJ, Haffty BG, Sohn LJ, et al. The conservative management of Paget’s disease of the breast with radiotherapy. Cancer 1997; 80: 1065–1072.

    CAS  PubMed  Google Scholar 

  198. Harris J, Morrow M, Bonadonna G. Cancer of the breast. In: Harris J, Lippman M, Morrow M, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996: 129.

    Google Scholar 

  199. Campana F, Forquet A, Ashby M. Presentation of axillary lymphadenopathy without detectable breast primary: experience at Institut Curie. Radiol Oncol 1989; 15: 321–325.

    CAS  Google Scholar 

  200. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases: updated management. Arch Surg 1990; 125: 210–214.

    CAS  PubMed  Google Scholar 

  201. Karlsson P, Holmberg E, Johansson KA, Kindblom LG, Carstensen J, Wallgren A. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996; 38: 25–31.

    CAS  PubMed  Google Scholar 

  202. American Cancer Society. Guidelines for the cancer related checkup. http://www.cancer.org/guide/guidchec.html 1997.

  203. National Cancer Institute. Breast cancer screening. In: PDQ: detection and prevention. http://cancernet.nci.nih.gov/clinpdq/ screening/Screening_for_breast_cancer_Physician.html 1997.

  204. National Cancer Advisory Board. National cancer advisory board mammography recommendations for women ages 40–49. http://cancernet.nci.nih.gov/news/ncabrec.html 1997.

  205. American College of Radiology. ACR standard for the perfor-mance of screening mammography. http://www.acr.org/departments/stand_accred/standards/pdf_standards/toc.pdf 1997.

  206. American College of Obstetricians and Gynecologists. ACOG news release: April 1997 press statement on mammography screening guidelines. http://www.acog.org/from_home/publications/press_releases/nr-mammos.html 1997.

  207. American Academy of Family Physicians. AAFP recommendations for periodic health examination. In: 1996–1997 AAFP Reference Manual: Clinical Policies. http://www.aafp.org/family/policy/camp/14.html 1997.

  208. US Preventive Services Task Force. Highlights: US Preventive Services Task Force Guide to Clinical Preventive Services. 2nd ed. http://www.ahcpr.gov/clinic/uspstf.html 1997.

  209. Shapiro S, Venet W, Strax P, et al. Current results of the breast cancer screening randomized trial: the Health Insurance Plan [HIP] of Greater New York study. In: Screening for Breast Cancer. Toronto: Sam Huber Publishing, 1988.

    Google Scholar 

  210. Morrison A, Brisson J, Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988; 80: 1540.

    CAS  PubMed  Google Scholar 

  211. Hurley SF, Kaldor JM. The benefits and risks of mammographie screening for breast cancer. Epidemiol Rev 1992; 14: 101.

    CAS  PubMed  Google Scholar 

  212. Alexander FE, Anderson TJ, Brown HK, et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 1994; 70: 542.

    CAS  PubMed  Google Scholar 

  213. Andersson I, Aspegren K, Janzon L, et al. Mammographie screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 943.

    CAS  PubMed  Google Scholar 

  214. Tabar L, Faberberg G, Duffy S, et al. Breast imaging: current status and future directions: update of the Swedish Two-County Program of mammographie screening for breast cancer. Radio! Clin North Am 1992; 30: 187.

    CAS  PubMed  Google Scholar 

  215. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study, 1: breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 1992; 147: 1458.

    Google Scholar 

  216. Bjurstam N, Björneld L, Duffy SW, et al. The Gothenburg breast screening trial. Cancer 1997; 80: 2091–2099.

    CAS  PubMed  Google Scholar 

  217. Ohuchi N, Yoshida K, Kimura M, et al. Improved detection rate of early breast cancer in mass screening combined with mammography. Jpn J Cancer Res 1993; 84: 807.

    CAS  PubMed  Google Scholar 

  218. Hayward J. The Guy’s trials on “early” breast cancer. World J Surg 1977; 1: 314.

    CAS  PubMed  Google Scholar 

  219. Sarrazin D, Le M, Arriagada R, et al. Ten-year results of a ran-domized trial comparing a conservative treatment to mastec-tomy in early breast cancer. Radiother Oncol 1989; 14: 177.

    CAS  PubMed  Google Scholar 

  220. Lichter A, Lippman M, Danforth D, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992; 10: 976.

    CAS  PubMed  Google Scholar 

  221. Van Dongen J, Bartelink H, Fentimen I, et al. Randomized clinical trial to assess the value of breast conserving therapy in Stage I and II breast cancer: EORTC 10801 trial. Monogr J Natl Cancer Inst 1992; 11: 15.

    Google Scholar 

  222. Blichert-Toft M, Rose C, Andersen J, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Monogr J Natl Cancer Inst 1992; 11: 19.

    Google Scholar 

  223. Krag D, Harlow S, Weaver D, Ashikaga T. Technique of sentinel node resection in melanoma and breast cancer: probe-guided surgery and lymphatic mapping. Eur J Surg Oncol 1998; 24: 89–93.

    CAS  PubMed  Google Scholar 

  224. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335–339.

    CAS  PubMed  Google Scholar 

  225. Borgstcin PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer [letter] [see comments]. Lancet 1997; 349: 1668–1669.

    Google Scholar 

  226. Giuliano AE. Intradermal blue dye to identify sentinel lymph node in breast cancer [letter; comment]. Lancet 1997; 350: 958.

    CAS  PubMed  Google Scholar 

  227. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997; 3: 336–340.

    CAS  PubMed  Google Scholar 

  228. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864–1867.

    CAS  PubMed  Google Scholar 

  229. Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg One 1998; 126–130.

    Google Scholar 

  230. Borgstein PJ, Pijpers R, Comans EF, Van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186: 275–283.

    CAS  PubMed  Google Scholar 

  231. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study [see comments]. N Engl J Med 1998; 339: 941–946.

    CAS  PubMed  Google Scholar 

  232. O’Hea BJ, Hill ADK, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186: 423–427.

    PubMed  Google Scholar 

Download references

Authors
  1. Helen A. Pass
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  2. Surgical Service, San Francisco VA Medical Center, San Francisco, California, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  3. Division of General Surgery, Duke University Medical Center, Durham, North Carolina, USA

    R. Randal Bollinger MD, PhD (Professor of Surgery, Professor of Immunology, Chief) (Professor of Surgery, Professor of Immunology, Chief)

  4. Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    Alfred E. Chang MD (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  5. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Stephen F. Lowry MD (Professor and Chairman) (Professor and Chairman)

  6. Division of General Surgery, University of California, San Francisco, San Francisco, California, USA

    Sean J. Mulvihill MD (Professor of Surgery, Chief) (Professor of Surgery, Chief)

  7. Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, Michigan, USA

    Harvey I. Pass MD (Professor of Surgery and Oncology, Chief of Thoracic Oncology) (Professor of Surgery and Oncology, Chief of Thoracic Oncology)

  8. Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

    Robert W. Thompson MD (Associate Professor of Surgery) (Associate Professor of Surgery)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pass, H.A. (2001). Benign and Malignant Diseases of the Breast. In: Norton, J.A., et al. Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57282-1_78

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57282-1_78

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63239-6

  • Online ISBN: 978-3-642-57282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation